A Comprehensive Supply Chain for Core Intermediates in Diabetes Treatment
March 6, 2026
End-to-end supply chain for anti-diabetic intermediates. Covering DPP-4, SGLT-2 inhibitors & GPR40 agonists. Stable, compliant, scalable.
A Comprehensive Supply Chain for Core Intermediates in Diabetes Treatment
In recent years, the number of people with diabetes worldwide has exceeded 589 million, spawning a blood sugar-lowering drug market worth over 100 billion yuan. With the normalization of centralized drug procurement policies, competition among pharmaceutical companies has extended from finished drug formulations to the upstream of the supply chain—the supply capacity of active pharmaceutical ingredients (APIs) and key intermediates has become crucial for success.
We focus on the field of antidiabetic pharmaceutical intermediates, precisely addressing the needs of mainstream clinical treatments, and have built an integrated product system from APIs to a full range of core intermediates.
The Billion-Dollar Diabetes Treatment Market Continues to Expand
According to core data from the China Type 2 Diabetes Prevention and Treatment Guidelines:
- The prevalence of diabetes in people aged 18 and above in my country has reached 11.9%, ranking first globally in total number of patients.
- Type 2 diabetes accounts for over 90%, and the proportion of patients with complications such as obesity and chronic kidney disease continues to rise.
- Clinical treatment needs have evolved from simply lowering blood sugar to a comprehensive upgrade to “lowering blood sugar + multiple benefits.”
Building a Full-Chain Mainstream Anti-Diabetes Product Matrix
Shandong Tianming Pharmaceutical Group has consistently kept abreast of the forefront of diabetes clinical treatment, focusing on leading global hypoglycemic drugs, and has built a full-chain product system covering raw materials and key intermediates, providing a one-stop solution for pharmaceutical companies’ upstream supply needs.
▶ Popular dual-target drug for lowering blood sugar and weight loss: Orforglipron
As a novel GPR40 agonist, Orforglipron has become a popular product in the field of blood sugar control due to its dual indications of type 2 diabetes and obesity, demonstrating great clinical and market potential in the treatment of metabolic diseases.
We have achieved large-scale production of Orforglipron and completed the entire supply chain layout of key intermediates for this product.
▶ Classic DPP-4 Inhibitors: Alogliptin and Linagliptin
DPP-4 inhibitors have long held a core position as first-line clinical drugs for type 2 diabetes due to their stable blood glucose lowering effect, low risk of hypoglycemia, and good patient tolerability. Alogliptin and linagliptin are the core products in this category, with widespread clinical application and stable market demand.
▶ Star SGLT-2 Inhibitors: Dapagliflozin and Empagliflozin
SGLT-2 inhibitors have become top-tier products in the blood glucose lowering drug market in recent years due to their clear cardio- and renal protective benefits in addition to blood glucose lowering. Dapagliflozin and Empagliflozin have been approved for multiple indications, including heart failure and chronic kidney disease, with continuously increasing market penetration and rapid growth in demand.
▶ A blockbuster drug for treating diabetic complications: Finerenone
As the course of diabetes increases, the incidence of complications such as diabetic nephropathy continues to rise, becoming a leading cause of death and disability among diabetic patients.
Finerenone , as the first nonsteroidal selective mineralocorticoid receptor antagonist approved for type 2 diabetes-related chronic kidney disease, is a blockbuster treatment in this field, with rapidly growing market demand.
Three Core Strengths Ensuring a Stable and Controllable Supply Chain
✅ R&D-driven, leading-edge technology
Our professional R&D team continuously optimizes synthesis processes, improving yields and reducing costs, meeting the full lifecycle needs from customized synthesis and process optimization to large-scale production.
✅ Rigorous quality control, compliance first
Our end-to-end quality control ensures our products meet domestic and international pharmacopoeia standards, with industry-leading impurity control, perfectly matching domestic and international registration requirements.
✅ Large-scale production capacity, stable supply. Our modern production base can achieve full-scale production from kilogram to ton levels, with ample capacity to fully cover the needs of all stages from R&D pilot-scale trials and pilot-scale amplification to commercial mass production, easily handling the surge in demand during centralized procurement.
The competition in the hypoglycemic drug market will ultimately return to a contest of core strengths across the entire industry chain. We will continue to deepen our expertise in the anti-diabetic field, providing higher-quality products and a more stable supply chain, working hand in hand with global pharmaceutical companies to safeguard the health of millions of diabetic patients.
CDMO vs. Direct Manufacturer: Which Model Fits Your API Strategy?
March 3, 2026
Drawing from on-the-ground experience in China’s top pharma clusters, this guide cuts through the jargon to reveal when to partner for complex innovation and when to buy from the workhorses of mature production.
Case Study: Improving Yield & Purity Through Route Optimization
February 27, 2026
This case study, based on publicly available academic literature and patents, focuses on the application of synthetic route optimization in improving the yield and purity of Active Pharmaceutical Ingredients (APIs).